

RxSight, Inc.

U.S. Securities Litigation

RxSight, Inc. (NASDAQ: RXST): RxSight, Inc. (“RxSight” or the “Company”) and certain of the Company’s senior executives have been sued for violations of the federal securities laws. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in RxSight securities. The case is pending in the U.S. District Court for the Central District of California and is captioned: *Makaveev v. RxSight, Inc., et al.*, No. 25-cv- 01596.

If you incurred losses on your investments in RxSight, you are encouraged to submit your information.

Why Was RxSight Sued for Securities Fraud?

RxSight is engaged in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses. The Company’s main product is its Light Adjustable Lens (LAL) that can be customized after cataract surgery through a series of non-invasive light treatments. These treatments, using a Light Delivery Device (LDD), adjust the lens’s shape and power to optimize vision based on the patient’s individual needs and preferences.

During the relevant period, the Company touted its strong LAL and LDD sales and failed to disclose “adoption challenges” in its products. In reality, RxSight was experiencing a slowdown in LAL utilization that was first noted in 2024.

The Stock Declines as the Truth Is Revealed

On April 3, 2025, before the market opened, RxSight cut its 2025 full-year revenue forecast citing a “softening” of the market that purportedly occurred “in the second half of 2024.” On this news, the price of RxSight stock declined roughly 38%, from \$26.12 per share on April 2, 2025, to \$16.21 per share on April 3, 2025.

Then on July 8, 2025, the Company further cut its 2025 full-year revenue forecast. RxSight attributed the adjustment to “the slower ramp in LAL utilization that was first noted in 2024” and “[a]doption challenges over the last few quarters.” On this

news, the price of RxSight stock declined roughly 38%, from \$12.79 per share on July 8, 2025, to \$7.95 per share on July 9, 2025.

What Are My Rights?

If you purchased or otherwise acquired RxSight securities, you may ask the Court no later than September 22, 2025, which is the first business day after 60 days from the date of publication of the notice of pendency, to appoint you as Lead Plaintiff through counsel of your choice. To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.

Contact Us

If you incurred losses on your investments in RxSight, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.

You can also contact:

Ross Shikowitz

ross@bfalaw.com

212.789.3619

All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by *Chambers USA*, *The Legal 500*, and *ISS SCAS*, and its attorneys have been named “Elite Trial Lawyers” by the *National Law Journal*, among the top “500 Leading Plaintiff Financial Lawyers” by *Lawdragon*, “Titans of the Plaintiffs’ Bar” by *Law360* and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over \$900 million in value from Tesla, Inc.’s Board of Directors, as well as \$420 million from Teva Pharmaceutical Ind. Ltd.

Attorney advertising. Past results do not guarantee future outcomes.